DDInter1400 DDInter1628
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Pazopanib {u} (Compound) binds {v} (Gene) MAP3K19
MAP3K19 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pazopanib {u} (Compound) upregulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Pazopanib {u} (Compound) binds {v} (Gene) RIOK2
RIOK2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Pazopanib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Protein Kinase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Ruxolitinib
Pazopanib {u} (Compound) downregulates {v} (Gene) SLC35A1
SLC35A1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Pazopanib {u} (Compound) upregulates {v} (Gene) MNAT1
MNAT1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Pazopanib {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Pazopanib {u} (Compound) binds {v} (Gene) STK16
STK16 {u} (Gene) regulates {v} (Gene) ARID4B
ARID4B {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Pazopanib {u} (Compound) binds {v} (Gene) MAP3K2
MAP3K2 {u} (Gene) interacts with {v} (Gene) MAP3K3
MAP3K3 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pazopanib {u} (Compound) binds {v} (Gene) TAOK3
TAOK3 {u} (Gene) interacts with {v} (Gene) LRRK2
LRRK2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Pazopanib (Compound) binds MAP3K19 (Gene) and MAP3K19 (Gene) is bound by Ruxolitinib (Compound)
Pazopanib (Compound) upregulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Ruxolitinib (Compound)
Pazopanib (Compound) binds RIOK2 (Gene) and RIOK2 (Gene) is upregulated by Ruxolitinib (Compound)
Pazopanib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class) and Protein Kinase Inhibitors (Pharmacologic Class) includes Ruxolitinib (Compound)
Pazopanib (Compound) downregulates SLC35A1 (Gene) and SLC35A1 (Gene) is downregulated by Ruxolitinib (Compound)
Pazopanib (Compound) upregulates MNAT1 (Gene) and MNAT1 (Gene) is downregulated by Ruxolitinib (Compound)
Pazopanib (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Pazopanib (Compound) binds STK16 (Gene) and STK16 (Gene) regulates ARID4B (Gene) and ARID4B (Gene) is upregulated by Ruxolitinib (Compound)
Pazopanib (Compound) binds MAP3K2 (Gene) and MAP3K2 (Gene) interacts with MAP3K3 (Gene) and MAP3K3 (Gene) is bound by Ruxolitinib (Compound)
Pazopanib (Compound) binds TAOK3 (Gene) and TAOK3 (Gene) interacts with LRRK2 (Gene) and LRRK2 (Gene) is bound by Ruxolitinib (Compound)